Hemostasis via platelet aggregation and activation

Hemostasis via platelet aggregation and activation refers to the physiological process in which platelets adhere to vascular injury sites, become activated by signaling molecules (such as collagen, ADP, thrombin), change shape, release pro-thrombotic factors, and aggregate to form a primary hemostatic plug. Central to this process are multiple membrane receptors (including P2Y12, Glycoprotein VI, GP IIb/IIIa, and protease-activated receptors) that transduce activation signals through complex intracellular pathways involving calcium mobilization and cytoskeletal remodeling. This finely tuned system is critical for preventing blood loss but, when dysregulated, can lead to excessive clotting (thrombosis) or bleeding disorders. Multiple therapeutic agents are clinically used to modulate this process by targeting key platelet signaling or adhesion molecules, most notably for the prevention of cardiovascular events or management of bleeding diatheses.

Other names

Platelet activation and aggregationPrimary hemostasisPlatelet plug formationPlatelet function in hemostasis

Inhibition of ADP-induced platelet activation via P2Y12 receptor antagonism; Inhibition of cyclooxygenase-1, reducing thromboxane A2 synthesis (aspirin); Inhibition of fibrinogen binding to GP IIb/IIIa, preventing aggregation; Inhibition of thrombin-induced platelet activation by PAR-1 antagonists.